Lista de obras - Jan Scicinski - Dominio Público Uruguay

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

artículo científico publicado en 2016

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

artículo científico publicado en 2016

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

artículo científico publicado en 2016

Analysis of Solid-Phase Reactions: Product Identification and Quantification by Use of UV-Chromophore-Containing Dual-Linker Analytical Constructs We thank Dr. P. Marshall for the provision of analytical data.

artículo científico publicado en 2000

Analytical construct resins for analysis of solid-phase chemistry

artículo científico publicado en 2002

Analytical techniques for small molecule solid phase synthesis

artículo científico publicado en 2002

Application of ReactArray Robotics and Design of Experiments Techniques in Optimisation of Supported Reagent Chemistry

article

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review

artículo científico publicado en 2012

Clean synthesis of α-bromo ketones and their utilisation in the synthesis of 2-alkoxy-2,3-dihydro-2-aryl-1,4-benzodioxanes, 2-amino-4-aryl-1,3-thiazoles and piperidino-2-amino-1,3-thiazoles using polymer-supported reagents

article published in 1999

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

artículo científico publicado en 2016

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

artículo científico publicado en 2015

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

artículo científico publicado en 2016

Development and Application of a Carbonyl-13C-Enriched Backbone Amide Linker for Solid-Phase Reaction Monitoring

article

Development of an indole safety-catch linker using analytical constructs

artículo científico publicado en 2004

Development of methods for the bioanalysis of RRx-001 and metabolites.

artículo científico publicado en 2014

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides

artículo científico publicado en 1998

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

artículo científico publicado en 2012

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

artículo científico publicado en 2015

Episensitization: Defying Time's Arrow

artículo científico publicado en 2015

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

artículo científico publicado en 2014

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

artículo científico publicado en 2015

Follow the ATP: tumor energy production: a perspective

artículo científico publicado en 2014

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

artículo científico publicado en 2015

Going viral: a review of replication-selective oncolytic adenoviruses

artículo científico publicado en 2015

Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

artículo científico publicado en 2002

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

artículo científico publicado en 2016

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

artículo científico publicado en 2015

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

artículo científico

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

artículo científico publicado en 2007

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

artículo científico publicado en 2017

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

artículo científico publicado en 2016

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

artículo científico publicado en 2015

No patient left behind: The promise of immune priming with epigenetic agents

artículo científico publicado en 2017

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy

artículo científico publicado en 2014

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

artículo científico publicado en 2015

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

artículo científico publicado en 2012

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

artículo científico publicado en 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

artículo científico publicado en 2016

Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics

artículo científico publicado en 2006

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

artículo científico publicado en 2012

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

artículo científico publicado en 2016

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

artículo científico publicado en 2016

RRx-001, A novel dinitroazetidine radiosensitizer

artículo científico publicado en 2016

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

artículo científico publicado en 2016

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

artículo científico publicado en 2016

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

artículo científico publicado en 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

artículo científico publicado en 2016

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

artículo científico publicado en 2013

Rewriting the epigenetic code for tumor resensitization: a review.

artículo científico publicado en 2014

Rockets, radiosensitizers, and RRx-001: an origin story part I.

artículo científico publicado en 2016

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

artículo científico publicado en 2015

Schwesinger Base, Polymer-supported

Single bead characterization using analytical constructs: application to quality control of libraries

artículo científico publicado en 2001

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

artículo científico publicado en 2011

Solid-phase development of a L-hydroxybenzotriazole linker for heterocycle synthesis using analytical constructs

artículo científico publicado en 2001

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

artículo científico publicado en 2016

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

artículo científico publicado en 2016

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

artículo científico publicado en 2015

The Touchstone Process: an ongoing critical evaluation of reiki in the scientific literature

artículo científico publicado en 2010

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

artículo científico publicado en 2014

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

artículo científico publicado en 2017

The implications of hyponitroxia in cancer

artículo científico publicado en 2014

The scarlet letter of alkylation: a mini review of selective alkylating agents.

artículo científico publicado en 2012

The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor

artículo científico publicado en 1998

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors

scientific article published on 01 January 1996

The war on cancer: a military perspective

artículo científico publicado en 2015

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

artículo científico publicado en 2016

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

artículo científico publicado en 2014

Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

artículo científico publicado en 2016

Lista de obras de Jan Scicinski

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Analysis of Solid-Phase Reactions: Product Identification and Quantification by Use of UV-Chromophore-Containing Dual-Linker Analytical Constructs We thank Dr. P. Marshall for the provision of analytical data.

Analytical construct resins for analysis of solid-phase chemistry

Analytical techniques for small molecule solid phase synthesis

Application of ReactArray Robotics and Design of Experiments Techniques in Optimisation of Supported Reagent Chemistry

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review

Clean synthesis of α-bromo ketones and their utilisation in the synthesis of 2-alkoxy-2,3-dihydro-2-aryl-1,4-benzodioxanes, 2-amino-4-aryl-1,3-thiazoles and piperidino-2-amino-1,3-thiazoles using polymer-supported reagents

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Development and Application of a Carbonyl-13C-Enriched Backbone Amide Linker for Solid-Phase Reaction Monitoring

Development of an indole safety-catch linker using analytical constructs

Development of methods for the bioanalysis of RRx-001 and metabolites.

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

Episensitization: Defying Time's Arrow

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Follow the ATP: tumor energy production: a perspective

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

Going viral: a review of replication-selective oncolytic adenoviruses

Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

No patient left behind: The promise of immune priming with epigenetic agents

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001, A novel dinitroazetidine radiosensitizer

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

Rewriting the epigenetic code for tumor resensitization: a review.

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Schwesinger Base, Polymer-supported

Single bead characterization using analytical constructs: application to quality control of libraries

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Solid-phase development of a L-hydroxybenzotriazole linker for heterocycle synthesis using analytical constructs

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

The Touchstone Process: an ongoing critical evaluation of reiki in the scientific literature

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

The implications of hyponitroxia in cancer

The scarlet letter of alkylation: a mini review of selective alkylating agents.

The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors

The war on cancer: a military perspective

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial